0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Kits > DLL4 > RES-A022

resDetect™ Biotinylated Human DLL4 ELISA Kit (Residue Testing)

For research use only.

Order Now

Product Details
Assay TypeIndirect-ELISA
AnalyteDLL4
Format96T
ReactivityHuman
Regulatory StatusRUO
Sensitivity< 7.81pg/mL
Standard Curve Range7.81 pg/mL-500 pg/mL
Assay Time2 hr 20 min
Suitable Sample TypeFor the quantitative determination of human DLL4 in Cell Culture Supernatants, Plasma, Serum.
Sample volume100 uL
Materials Provided
IDComponentsSize
RES022-C01Pre-coated Anti-DLL4 Antibody Microplate1 plate
RES022-C02Biotinylated Human DLL4 Standard20 μg
RES022-C03Streptavidin-HRP50 μL
RES022-C0410xWashing Buffer 50 mL
RES022-C052xDilution Buffer50 mL
RES022-C06Substrate Solution12 mL
RES022-C07Stop Solution7 mL
  • Background
    Biotinylated Human DLL4 ELISA Kit is based on ELISA sandwich method and designed to measure biotinylated human DLL4 levels in cell culture supernates, serum, and plasma. It contains recombinant biotinylated human DLL4 and a pair of antibodies against the recombinant factor, which are provided by ACROBiosystems. Results are obtained by four parameter logistic curve that were parallel to the standard curves obtained. The verification results indicate that this kit can be used for the quantitative determination of GMP biotinylated human DLL4 (ACROBiosystems, cat#GMP-DL4H23) concentrations. The specificity has been verified.
  • Application

    The Biotinylated Human DLL4 ELISA KIT (Residue Testing) was developed for the detection and quantitative determination of GMP biotinylated Human DLL4 (ACROBiosystems, cat#GMP-DL4H23) concentration.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving.

    Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This assay kit employs a standard sandwich-ELISA format, providing a rapid detection of Human Fc Tag DLL4. The kit consists of Pre-coated Anti-DLL4 Antibody Microplate and Human Fc Tag DLL4 Standard and Biotin-Anti-DLL4 Antibody and Streptavidin-HRP and buffers.

    Your experiment will include 5 simple steps:

    a) Bring all reagents to room temperature(20℃-25℃) before use.

    b) Add your sample to the plate and take the Biotinylated Human DLL4 Standard. The samples and standard are diluted by Dilution Buffer.

    c) Wash the plate and add the Streptavidin-HRP diluted by Dilution Buffer to the plate.

    d) Wash the plate and add TMB.

    e) Stop the substrate reaction by adding diluted acid. Absorbance (OD) is calculated by the absorbance at 450 nm minus the absorbance at 630 nm to remove background disturbance before statistical analysis. The OD Value reflects the amount of bound protein.

Typical Data Please refer to DS document for the assay protocol.
 DLL4 TYPICAL DATA

For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The following example data is for reference only.

  • Background: DLL4
    Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €350.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message